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Abstract: The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further
exploration of improved poxvirus vector systems that can yield better immune responses and protec-
tion. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU
gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and compared to the equiv-
alent recombinant modified vaccinia Ankara (MVAGC5). In vitro characterization confirmed that
cells infected with recombinant LSDV produced Gag virus-like particles containing Env, and that
Env expressed on the surface of the cells infected with LSDV was in a native-like conformation. This
candidate HIV-1 vaccine (L) was tested in a rabbit model using different heterologous vaccination
regimens, in combination with DNA (D) and MVA (M) vectors expressing the equivalent HIV-1
antigens. The four different vaccination regimens (DDMMLL, DDMLML, DDLMLM, and DDLLMM)
all elicited high titers of binding and Tier 1A neutralizing antibodies (NAbs), and some regimens
induced Tier 1B NAbs. Furthermore, two rabbits in the DDLMLM group developed low levels
of autologous Tier 2 NAbs. The humoral immune responses elicited against HIV-1 Env by the
recombinant LSDVGC5 were comparable to those induced by MVAGC5.
Keywords: LSDV; lumpy skin disease; vaccine; HIV-1; vector; poxvirus; VLP
1. Introduction
The demand for new vaccines is ever increasing, be it for different pathogens or
additional booster vaccines against a single pathogen. Despite the recent developments
in vaccine technology [1], there remains a need for additional vaccine vectors, and live
attenuated viral vectors are no exception [2]. The repeated use of the same live attenuated
viral vector can result in anti-vector immunity, which could either be beneficial to the
improvement of vaccine immunogenicity, or detrimental in the enhancement of viral
infections [3]. Although low levels of antibodies can augment the uptake of a viral vector,
high levels of pre-existing antibodies can reduce vaccine’s efficacy by the neutralization
of the vector or inhibition of B cell responses [3]. Adenoviruses are widely used as live
Vaccines 2021, 9, 1281. https://doi.org/10.3390/vaccines9111281 https://www.mdpi.com/journal/vaccines
Vaccines 2021, 9, 1281 2 of 18
attenuated vaccine vectors. The human immunodeficiency virus 1 (HIV-1) STEP trial
showed how pre-existing antibodies to adenovirus 5 (Ad5) resulted in the increase in HIV-1
infection in men vaccinated with the MRKAd5 HIV-1 Gag/Pol/Nef vaccine [4]. Since
then, rare human adenovirus serotypes, as well as non-human primate adenoviruses, have
been developed to overcome the problem of pre-existing antibodies; refinements to the
adenovirus vector platform are also ongoing [5].
It has been forty years since the start of the HIV pandemic [6] and a vaccine for the
disease remains unavailable. Despite decades of research into HIV-1 vaccine development,
a vaccine inducing durable neutralizing immunity remains elusive [7–9]. Of the many
different regimens tested in clinical trials, the DNA–MVA–protein regimen appears to be
one of the most promising [10]. Recently, the recombinant MVA, expressing gp150, has been
shown to induce a more durable antibody response than soluble gp120 protein following
a DNA prime [11]. This study evaluates the HIV Env-specific antibody responses across
ten different HIV vaccine regimens; MVA boosted longer lasting responses in comparison
to protein boosts but of a lower magnitude [11]. In a comparison between DNA, MVA,
and the vesicular stomatitis virus (VSV) as primes to a protein boost, MVA elicited higher
binding and neutralizing antibodies to HIV Env than the other vectors in macaques [12].
Different vectors and adjuvants activate specific cellular pathways of immunogenicity,
and specific B cell transcriptomic signatures have been associated with protection [11].
Likewise, different poxviruses exhibit different transcriptomic profiles [13]. The unique re-
sponse elicited by the host to different vectors means that vectors can be selected according
to the desired immune response. Poxvirus genera, historically, have been characterized by
cross-neutralization and host range [14]; in particular, no cross-immunity has been shown
between capripoxviruses and other poxvirus genera [15]. Lumpy skin disease virus (LSDV)
is host-restricted to ruminants and, although there is some cross-neutralization of sheeppox
virus (SPPV), this protection is only partial when cattle are vaccinated with SPPV and are
subsequently challenged with LSDV [16]. Like capripoxviruses, orthopoxviruses have
been shown to cross-neutralize within genera [17,18]; however, there is limited informa-
tion on the cross-neutralization between different poxvirus genera. The neutralization of
poxviruses is complex, with no single protein eliciting a neutralizing antibody response.
There are six proteins required for a broad neutralization of the orthopoxviruses compris-
ing vaccinia, variola, cowpox, and monkeypox; these are the mature virion (MV) proteins
A27, L1, H3, and D8, and the extracellular virion (EV) surface proteins B5 and A33 [18].
In addition to vaccinia viruses (MVA and NYVAC), two avipoxviruses (canarypoxvirus
(ALVAC) and fowlpoxvirus) have been extensively tested as vaccine vectors for HIV-1
vaccines [19]. There is no data available on the cross-neutralization of viruses within the
Avipoxvirus genus, but whole genome sequence analysis has revealed the avipoxviruses to
be highly diverse, genetically [20,21]. Poxviruses provide great potential for expanding
the repertoire of vaccine vectors available for the future vaccine development for either
humans or animals.
The application of veterinary research to human disease prevention is gaining momen-
tum as part of a One Health approach to tackling global health problems [22]. The present
study shows how a widely used live attenuated bovine vaccine, LSDV, can be used as a
host-restricted vaccine vector for a human pathogen, HIV-1. Poxviruses are one of the
best platforms for recombinant vaccine vectors. Recently, an Ebola vaccine based on the
combination of an adenovirus and MVA vaccine vectors has been registered [23]. There
are only a limited number of poxviruses that have been tested in human clinical trials;
namely, vaccinia virus (VV), the attenuated host-restricted vaccinia viruses MVA and NY-
VAC, fowlpox virus, and ALVAC (based on the canarypox virus) [11,24–26]. Our group is
investigating lumpy skin disease virus (LSDV) as a non-replicating vaccine vector as it is
not able to replicate and complete the life cycle in non-ruminant hosts. LSDV, a member
of the Capripoxvirinae genus of the Poxviridae family, causes significant morbidity in cattle
in Africa and, more recently, in the Middle East and Europe [27]. The Neethling vaccine
strain of LSDV has a proven safety profile, does not cause disease in immunosuppressed
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mice, and has already been investigated as a host-restricted vaccine vector for rabies and
HIV-1 [28–30]. Encouragingly, vaccination with LSDV expressing rabies virus glycoprotein
was able to protect mice from rabies challenge [30]. LSDV was also compared to MVA in
both homologous and heterologous vaccine regimens as a potential HIV-1 vaccine vector
in mice and macaques, eliciting high-magnitude, broad, and balanced CD4+ and CD8+ T
cell responses. These responses were far greater than those observed in MVA or LSDV
alone [28,29]. Both the LSDV and MVA HIV-1 vaccines expressed a polyprotein Grttn,
consisting of Gag, RT, Tat, and Nef, but no Env and therefore antibody responses to Env
were not tested in these previous studies.
With advances in HIV-1 vaccine research, vast improvements have been made in
vaccine design to improve the induction of neutralizing antibodies [31,32]; our group has
incorporated many of these features into making improved candidate vaccines against
HIV-1 [33–37]. The CAP256 superinfecting viral envelope (CAP256.SU) was selected for
use in this study as the patient from which the virus was isolated developed broadly
neutralizing antibodies (bNAbs) [38]. In addition, this envelope was sensitive to several
prototype bNAbs [39] and showed an enhanced reactivity to some bNAb precursors [40,41].
The Grttn polyprotein was replaced by HIV-1 CAP256.SU Env and truncated to gp150;
the native leader sequence was replaced with the tissue plasminogen activator (TPA)
leader peptide; the furin cleavage site was replaced with a flexible Gly-rich linker se-
quence (GGGGSGGGGSG); and a stabilizing I559P mutation was introduced into the
gp41 region. In addition, a mosaic Gag gene was used so that virus-like particles (VLPs)
could be produced. MVAGC5, expressing GagM and CAP256.SU gp150, was tested in
rabbits in a DNA–MVA–protein regimen, with two doses of each of the vaccines. Tier1B
and low levels of Tier 2 autologous neutralizing antibodies were produced by 4/5 rab-
bits [36]. The DDMMPP vaccine regimen is presently being tested in a non-human primate
model [42]. The aim of this study is to construct and test the equivalent recombinant LSDV
vaccine (LSDVGC5) to determine how it would compare to MVAGC5, and whether the
neutralizing antibody response can be improved by the heterologous poxvirus vaccination.
The vaccines are based on the HIV-1 subtype C, as this is the major subtype circulating in
South Africa [43]. In addition to using improved HIV-1 antigen genes, improvements were
also made to the construction of recombinant LSDV. Instead of using the Neethling LSDV
vaccine strain as a parent virus backbone, the improved nLSDVSODis–UCT backbone
was used [44] and recombination was targeted to an intergenic region between two highly
conserved genes, LSDV ORFs 49 and 50. Previously, the HIV-1 Grttn gene was inserted
into the ribonucleotide reductase gene [29], which would have caused the further attenua-
tion of the LSDV. The previous construct contained the Escherichia coli xanthine-guanine
phosphoribosyl transferase gene (Gpt) for positive metabolic selection, as well as the
beta-glucuronidase (GUS) marker gene. The candidate vaccine made in the present study
contained no metabolic selection gene and expressed the fluorescent protein, mCherry,
instead of GUS.
The recombinant LSDV (L) expressing HIV-1 CAP256.SU gp150 and the HIV subtype
C mosaic Gag (GagM) was constructed and tested in a rabbit model using different het-
erologous vaccination regimens, in combination with DNA (D) and MVA (M). Groups
of 5 rabbits were inoculated with 4 different vaccine regimens: DDMMLL; DDMLML;
DDLMLM; and DDLLMM at 0, 4, 8, 12, 16, and 20 weeks. Binding and neutralizing anti-
body responses elicited by the different regimens were compared. LSDVGC5 was shown
to elicit antibody responses comparable to MVAGC5, against HIV-1 Env.
2. Materials and Methods
2.1. Antibodies, Cell Lines, Media, and Reagents
Goat anti-HIV-1 gp160 (MRC ADP 72 408/5104); rabbit anti-HIV-1 p24 (Gag) (ARP 432);
donkey anti-goat IgG Cy3 or FITC; and donkey anti-rabbit IgG Alexa 647 (Life Technologies,
Oslo, Norway) were used for immunofluorescence assays. The goat anti-human IgG-FITC
(Fc-specific) antibodies (ab 97224, abcam, Cambridge, UK) were used for live-cell staining.
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Goat anti-HIV-1 gp120 (Bio-Rad 5000–0557, Bio-Rad, Watford, UK); goat anti-HIV-1 p24
(Gag) (Bio-Rad 4999–9007, Bio-Rad, Watford, UK); and mouse monoclonal anti-goat/sheep
IgG–AP GT34 (Sigma, Saint Louis, MO, USA) were used for Western blotting. The anti-
HIV-1 Env human monoclonal antibodies (MAbs) PG9, PGT128, CAP256 VRC26.08, and
VRC01 were expressed in FreeStyle 293F cells (Life Technologies, Oslo, Norway) using
the PEIMAX transfection reagent (Polysciences, Warrington, PA, USA). The monoclonal
antibodies were purified from cell-free supernatants after 6 days using protein A affinity
chromatography [39].
MBDK and HeLa cells (supplied by ATCC) were grown in Dulbecco’s Modified Eagle
Medium (DMEM) (high glucose), plus L-glutamine (Lonza), plus 10% of fetal calf serum,
plus 10% of penicillin-streptomycin (Pen-Strep) (both from Gibco).
2.2. Design and Construction of DNA, MVA, and LSDV Vaccines Expressing Env and Gag
The sequence of the CAP256.SU gp160 (clone CAP256.206sp.032.C9) has been previ-
ously described (GenBank: KF241776.1) [45]. The Env sequence was modified, as previously
described [36]. As shown in Figure 1, the native leader sequence was replaced with the
tissue plasminogen activator (TPA) leader peptide, the furin cleavage site was replaced
with a flexible linker (FL) consisting of GGGGSGGGGSG, and an isoleucine was mutated
to proline (I559P) in the gp41 region.
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Figure 1. The design of vaccines. (a) The schematic representations of gene coding sequences for the HIV wild-type gp160
envelope, the gp150-FL-IP envelope immunogen, and the subtype C mosaic Gag (GagM). The native signal sequence
(HIV-1 SP) was replaced with the tissue plasminogen activator signal sequence (TPA SP) for the gp150 antigen, the furin
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The expression cassette containing the gp150 was inserted between ORFs I8R and G1L and the GagM between ORFs A11R
and A12L. (c) A diagram showing the design of LSDVGC5. An expression cassette containing gp150 and GagM was inserted
between ORFs 49 and 50. The gray arrows indicate the primers used for PCR and the dotted line indicates the fragment
amplified by PCR. (d) The PCR confirmation of LSDVGC5. DNA was extracted from MBDK cells infected with LSDVGC5
and subjected to PCR. Fragments were separated by agarose gel electrophoresis. M = GeneRuler 1kb DNA ladder (Thermo
Fisher Scientific, Waltham, MA, USA).
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As previously described, the mammalian expression plasmid pTHPcapR [47] was
used to construct DNA vaccines expressing the gp150; pMExT CAP256 gp150-FL-IP [36];
and subtype C mosaic Gag, pTJDNA4 [33]. In this study, the DNA vaccines pMExT CAP256
gp150-FL-IP and pTJDNA4 were administered together and are referred to as DNAGC5.
All the DNA vaccines were synthesized using GenScript (Hong Kong).
MVAGC5 was constructed as previously described and shown in Figure 1b [36].
The expression cassette containing the gp150 was inserted between the I8R and G1L open
reading frames (ORFs), and the gagM gene was inserted between the ORFs A11R and A12L;
both genes were placed under the control of the mH5 promoter.
The recombinant LSDV (LSDVGC5) was constructed using nLSDVSODis–UCT as a vec-
tor backbone [44]. For the construction of LSDVGC5, the green fluorescing LSDV(SODis)BEFV-
Gb [48] was used as a parent virus so that the gene cassette between ORFs 49 and 50 could
be replaced with a gene cassette, including the mCherry gene, which encodes a red fluo-
rescing protein. A transfer vector was constructed in which the gene cassette—containing
TPA-gp150-FL-IP under the control of the VACV mH5 promoter, gagM under the control of
the pLEO promoter, and the fluorescent marker mCherry under the control of the modified
fowl poxvirus promoter [49]—was placed in between flanking sequences from the LSDV
49–50 locus (Figure 1b) [50]. Primary lamb tests cells were infected with LSDV(SODis)BEFV-
Gb and transfected with the transfer vector. Three days after the infection and transfection,
cells were freeze–thawed, and the viral lysate was passaged in the MBDK cells. Single, red
fluorescing foci were repeatedly picked and passaged in the MBDK cells until no parent
virus (green fluorescent foci) was visible. A single focus isolated from a 96-well plate was
used to prepare a large-scale stock of LSDVGC5 in hyperflasks. T75 flasks of MBDK cells
were infected at an MOI of 0.005 and incubated at 37 ◦C for 2 h with gentle mixing every
fifteen minutes. The contents of the flasks were then used to set up hyperflasks which
were allowed to grow for 11 days until most of the cells had lifted. Three freeze–thaw
cycles were performed, and the supernatant containing the virus was cleared by low-speed
centrifugation. The remaining virus in the pellet was released by lysis with 0.1 mM Tris
(pH 9), and the second supernatant was added to the previous one after another low-speed
spin. The LSDV was concentrated by centrifugation through a 36% sucrose cushion and
resuspended in PBS plus 10% of glycerol. The recombinant (LSDVGC5) was then aliquoted
and stored at −80 ◦C for downstream usage. Titers were determined in the MBDK cells, in
which mCherry-positive plaques were counted 72 h after the infection of a serial dilution
range. High-titer stocks were screened for the correct integration of the targeting construct
by PCR and sequencing (analyzed with CLC Main Workbench, Qiagen). The expression of
the mosaic Gag and Env was verified by Western blot analysis and immunofluorescence.
2.3. PCR Confirmation of the LSDV Recombinant
The insertion of the foreign gene cassette between LSDV ORFs 49 and 50 was con-
firmed by polymerase chain reaction (PCR), followed by agarose gel electrophoresis
and Sanger DNA sequencing of the amplicon. The primer sequences used were 5′-
GAGTGAAGCCTGGAACAT-3′ (forward primer) and 5′-ACTCTATCGCATCTGGAAACT-
3′ (reverse primer). These generated fragment sizes of 1329 bp for control virus nLSDVSODis–
UCT and 5900 bp for LSDVGC5. The Phusion High-Fidelity enzyme was used with the
HF Buffer (New England BioLabs, Ipswich, MA, USA). The following thermocycling pa-
rameters were used for all PCR reactions: initial denaturation at 98 ◦C for 5 min followed
by 40 cycles of denaturation at 98 ◦C for 30 s, annealing at 56 ◦C for 30 s, extension at
72 ◦C for 6 min, and a final extension at 72 ◦C for 10 min. PCR products were sepa-
rated on 0.8% agarose gels, containing 0.5 µg/mL ethidium-bromide, by electrophoresis in
1xTBE buffer.
2.4. Live-Cell Staining Using Human Monoclonal Anti-Env Antibodies
To assess the structural integrity of Env expressed by HeLa or MBDK cells infected
with LSDVGC5, binding to the anti-Env human monoclonal antibodies PG9, PGT128,
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CAP256 VRC26.08, and VRC01 was tested as previously described [36]; however, the
secondary antibody anti-human IgG FITC (ab 97224, abcam, Cambridge, UK) was used.
2.5. VLP Isolation and Characterization
T150 flasks of the MBDK cells were infected with the LSDV at an MOI of 0.5. After
48 h, VLPs were isolated as follows: the media was cleared with a low-speed spin (5 min at
275 g), the supernatant was removed and transferred to centrifuge tubes, and centrifugation
was performed at 47,000× g for 90 min at 4 ◦C with no break. Pellets containing VLPs were
reconstituted in 100 µL of PBS (pH 7.4). Freshly activated carbon grids were coated with
VLP preparations, stained with uranyl acetate, imaged onto an FEI Tecnai F20 transmission
electron microscope (Thermo Fisher (formerly FEI), Eindhoven, The Netherlands), and
fitted with a DE-16 camera (Direct Electron, San Diego, CA, USA).
For the preparation of thin sections, the MBDK cells infected with the LSDV from
the T150 flasks were collected by scraping, spun briefly, washed with PBS, and then fixed
overnight in 2.5% of glutaraldehyde in PBS (4 ◦C). The fixed cells were then washed twice
in PBS and resuspended in 2% low melting point agarose and processed as described
earlier [33].
2.6. Rabbit Immunizations
Female New Zealand White rabbits were bred and housed in the animal facility of
the Faculty of Health Sciences at the University of Stellenbosch. Groups of 5 rabbits were
used in the experiment. The rabbits were 4 to 5 months old and over 2 kg in weight at
the start of the experiment. All the animal procedures were approved by the UCT Animal
Research Ethics Committee (reference UCT AEC 015–051 and 019–015) and performed
by trained animal technologists. DNA, MVA, and LSDV vaccines were administered
intramuscularly into the hind leg at 100 µg (100 µL of each), 108pfu (500 µL), and 107pfu
(500 µL), respectively, using the Pharmajet® Stratis (Pharmajet, Golden, CO, USA) device.
The vaccination schedule is shown in Figure 5a.
2.7. Anti-Env Enzyme-Linked Immunosorbent Assays (ELISA) and HIV Neutralization Assays
Env binding antibody titers in the rabbit sera were determined, as previously de-
scribed [36]. The standardized TZM-bl pseudovirus neutralization assay was used to
determine neutralizing antibody titers, as described previously [36].
2.8. Statistical Analysis
All statistical analysis was performed using the GraphPad Prism 5.0 (San Diego, CA,
USA). Both one-way and two-way ANOVA were performed with Bonferroni post hoc
testing. A non-parametric two-tailed Mann–Whitney test was also used when comparing
the differences between the two groups.
3. Results
3.1. Design and Construction of Vaccines
The DNA, MVA, and LSDV vaccines were designed to express a membrane-anchored
gp150 (Env) with the aim that the co-expression with the mosaic Gag (GagM) would lead to
the incorporation of Env into Gag virus-like particles (VLPs). Previous work carried out by
our group has shown that the presentation of Env on the surface of Gag VLPs leads to better
neutralizing immune responses, when compared to the HIV-1 envelope protein alone [36].
The envelope sequence was modified as previously described [36] and shown in Figure 1a,
(CAP256 gp150-FL-IP). The mammalian expression vector, pTHPCapR, containing the
porcine circovirus enhancer element, which has been shown to give increased antigen
expression and immunogenicity [47], was utilized for the DNA vaccines expressing Env
and Gag (DNAGC5) [33,36]. The recombinant MVA vaccine, MVAGC5, contains the HIV-1
subtype C mosaic Gag gene (GagM) inserted between the A11R and A12L ORFs and the
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env gene inserted between ORFs I8R and G1L, as shown in Figure 1b [36]. Both genes are
under the control of the VACV mH5 promoter.
To construct LSDVGC5, a transfer vector was designed containing the HIV-1 envelope
gp150 gene under the control of the mH5 promoter, the GagM gene under the control of
the pLEO promoter, and the mCherry marker gene under the control of a modified fowl
poxvirus promoter. This expression cassette was inserted between the highly conserved,
convergent LSDV ORFs 49 and 50 (Figure 1c). The recombinant was confirmed to be correct
by PCR (Figure 1d) and sequencing.
3.2. Expression of Env and Gag
The expression of the Env and Gag proteins in cells infected with the LSDV vaccine
was confirmed by Western blotting and immunofluorescent staining (Figure 2). In vitro
expression of Env and Gag has previously been confirmed for the DNA and MVA vac-
cines [34,36].
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3.3. Quaternary Structure of Env Expressed In Vitro
Live cell staining was carried out to assess the quaternary structure of the Env ex-
pressed on the surface of cells infected with the LSDV vaccine. All four human monoclonal
antibodies (CAP256 VRC26.08, PGT128, VRC01, and PG9) tested, bound, to some extent, to
the Env expressed by LSDVGC5 (Figure 3). The live cell staining of the cells transfected
with the DNA vaccine or infected with the MVA vaccine was carried out previously with a
larger panel of monoclonal antibodies [34,36]. A summary of the live cell staining results
for the Env expressed by all three vaccines (DNA, MVA, and LSDV) is given in Figure 3b.
CAP256 VRC26.08 and PG9 bound to a quaternary epitope on the V1/V2 of native trimers,
indicating that at least some of the Env expressed by the three different vaccines was in a
native-like conformation. The binding of PGT128 verified that the V3 glycan supersite was
intact, and the binding of VRC01 confirmed the presence of the CD4 binding site.
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Figure 3. The characterization of Env expressed on the surface of cells transfected ith D or
infected with V 5 a 5 cci es. (a) the live cell staining of cells i fected ith
LSDVGC5, using MAbs CAP256 VRC26.08, PGT128, VRC01 (HeLa cells), or PG9 (MBDK cells).
The infection with LSDV is visualized by mCherry expression (red). The binding of MAbs was
detected with anti-human IgG-FITC (green). Scale bar = 50 µm. (b) Summary of MAbs to HIV Env
that bound to cells transfected or infected with DNA, MVA, and LSDV vaccines expressing Env
and Gag.
3.4. Confirmation of Virus-like Particle Formation
All three vaccine candidates produced virus-like particles, as shown by transmis-
sion electron microscopy (TEM) of transfected/infected cells (Figure 4a,c), and previ-
ously confirmed for the MVA and DNA vaccines [34,36]. No VLPs were seen for un-
infected/untransfected cells or cells infected with parental MVA or LSDV, confirming
that VLP production was vaccine specific. Western blotting also showed that the VLPs
contained both Gag and Env (Figure 4b).
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bar = 200 nm.
3.5. Heterologous Vaccination with DNA and Two Different Poxvirus Vectors
The use of LSDV and MVA vaccines in different combinations following two DNA
primes was compared, as previous studies carried out in macaques by our group had
shown that an MVA/LSDV heterologous prime boost elicited broader, higher magnitude
T cell responses than either vector alone [28]. Four different vaccination regimens were
compared, as shown in Figure 5a. All four regimens elicited similar levels of binding and
Tier 1A neutralizing antibodies throughout the time course (Figure 5b,c and Figure 6a–c
respectively). Two DNA followed by two MVA inoculations (DDMM) elicited significantly
higher levels of Tier 1A Nabs compared to two DNA followed by two LSDV inoculations
(DDLL) (p > 0.008), but no other differences were seen between the different groups
(Figure 6b). The DDLMLM regimen appeared to elicit slightly better Tier 1B neutralizing
antibodies in 5/5 rabbits, compared to 2/5 in the DDMLML regimen and 3/5 in the
DDLLMM regimen, with slightly higher mean titers; however, this was not significant,
probably due to the low numbers (Figure 6d,e). Similarly, only rabbits vaccinated with
the DDLMLM regimen developed autologous CAP256.SU Tier 2 neutralizing antibodies.
These results showed that the LSDV-vectored vaccine elicited very similar responses to
MVAGC5, and LSDV could therefore be used as an additional vaccine vector for HIV-1 and
other human pathogens.
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Figure 5. The antibody responses elicited in rabbits inoculated with different combinations of DNA, MVA, and LSDV
vaccines. (a) Rabbit immunization protocol. All vaccines were administered using the Pharmajet Stratis® device. (b) Time
course showing the binding antibodies to Env (ELISA) in rabbit sera. When no binding was observed, the end point titer
was plotted as 10. Data were plotted as the mean +/− SEM. (c) the neutralizing antibody titers in rabbit sera measured
using the TZM-bl assay.
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4. Discussion
Several features make poxviruses ideal vectors for recombinant vaccines: poxviruses
are able to accommodate relatively large pieces of foreign DNA; they are easy and cheap
to manufacture; they are stable as freeze-dried preparations for long periods of time; they
replicate in the cytoplasm, not the nucleus, and are therefore unlikely to get integrated into
the host genome; and can induce long-lasting cellular and humoral immune responses.
As discussed in a comprehensive review on recombinant capripoxviruses as vaccine vectors
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for delivering foreign antigens, recombinant LSDVs have been constructed expressing anti-
gens against a variety of diseases, including rinderpest; peste des petits; Rift Valley fever;
bluetongue; rabies; bovine ephemeral fever; foot and mouth disease; HIV; hydatidosis;
and brucellosis [51]. Most of these recombinant LSDV vaccines induced effective immune
protection when assessed. In this study, LSDV was evaluated as an HIV-1 vaccine vector
and compared to MVA, expressing identical antigens.
Poxviruses, like most other viral vectors, do not perform optimally when used repeat-
edly in the same host due to vector immunity. Therefore, DNA is often used to prime the
immune response which can be boosted by two subsequent MVA vaccinations. Studies
have shown that a third MVA vaccination does not boost unless a substantial amount of
time has passed [52]. This provides justification for the development of other poxvirus
vectors, such as LSDV, for instances where additional boosts are necessary.
MVAGC5 had an improved design compared to the SAAVI MVA-C vaccine design [53]
and included the use of different promoters for the Gag and Env genes; a replacement of the
native Gag gene with the subtype C mosaic Gag antigen which forms virus-like particles;
and the modification of Env by sequence changes to improve stability and transport to the
cell surface [35]. A further improvement was based on the CAP256 superinfecting viral
envelope (CAP256.SU) protein which had a flexible glycine linker and I559P mutation. In a
previous study, heterologous prime-boost regimens with DNAGC5, MVAGC5, and protein,
elicited autologous Tier 2 neutralizing antibodies (NAbs) and high-titer binding antibodies
to the matching CAP256 Env and CAP256 V1V2 loop scaffold [36]. The presence of binding
antibodies (ELISA), Tier 1 Nabs, and antibodies to V2 have been reported to correlate
with the protection from SIV challenge [52,54]. The mosaic HIV subtype C Gag had been
shown to induce T cell responses in mice [33]. T cell responses to Gag are associated
with the control of HIV and it is therefore desirable to include Gag in HIV vaccines [32].
In line with the improved design of MVAGC5, LSDVGC5 (expressing HIV-1 CAP256.SU
gp150 and the subtype C mosaic Gag) was constructed and shown to produce HIV-1 Gag
VLPs containing Env. The conformation of the Env expressed on the surface of the cells
infected with LSDVGC5 was characterized by live cell staining with bNAbs. The Env
bound trimer-specific bNAb, CAP256 VRC26.08, indicating that a proportion of the Env
was in a native-like trimeric conformation as shown for MVAGC5 [34,36]. However, the
live staining, with MAb CAP256 VRC26.08, of cells infected with LSDVGC5 appeared to be
slightly lower than that of the other MAbs that do not detect native-like trimers (Figure 3),
possibly indicating that not all of the envelopes expressed had a native-like trimer structure.
However, this was not quantified as this is difficult to do using fluorescent microscopy.
This could explain why such low levels of autologous Tier 2 NAbs were elicited by the
different vaccination regimens. Nevertheless, this is highly encouraging and confirms
that some of the heterologously expressed antigens retain the desired conformation when
expressed in vitro. Recapitulating bNAb epitopes is generally considered a hallmark of
a good Env immunogen and, in many cases, this may require the extensive engineering
of the antigen sequence. It is plausible that presenting Env in a membrane-bound context
helped stabilize the protein. Clade C stable, native-like Env trimers are often more difficult
to produce than other clades [55]. In this study, the only modifications made to the Env to
improve stability and folding were to replace the furin cleavage site with a ten amino acid
flexible linker and to include the I559P mutation in gp41. Further targeted modifications to
the CAP256.SU Env sequence, to improve the structure and antigenicity, could increase the
levels of stable, native-like CAP256.SU [56–61].
The role and importance of different types of antibodies in the protection against HIV
infection is still not fully understood. In the RV144 trial, HIV-1-specific IgG3 distinguished
two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with
the decreased risk of HIV-1 infection [62]. Antibody-dependent cell-medicated cytotoxicity
and antibody-dependent cell-mediated virus inhibition also play a role in viral control
in macaque models [63] and clinical trials [64,65]. The immunogenicity of our candi-
date HIV-1 vaccine was tested in a rabbit model using different heterologous vaccination
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regimens, in combination with DNAGC5 and MVAGC5 expressing matching antigens:
DDMMLL; DDMLML; DDLMLM; and DDLLMM at 0, 4, 8, 12, 16 and 20 weeks. Ten of
the twenty rabbits in this study developed binding antibody responses to HIV Env after
two DNAGC5 inoculations, whereas in previous studies carried out using this vaccine
none of the rabbits developed binding antibodies at this time point [34,36]. The responding
and non-responding animals were fairly evenly distributed between the different groups,
with 2/5 animals responding in the first two groups and 3/5 in the second two groups.
All rabbits developed high levels of binding antibodies after one poxvirus immunization,
which substantially boosted the antibody response observed after the two DNA priming
vaccines. These antibodies may have Fc receptor-mediated functions which is of interest,
as non-neutralizing functional antibodies can play a critical role in the protection from
HIV infection [66]. It should be noted that LSDVGC5 was given at a ten-fold lower dose
than MVAGC5; this was because LSDV does not reach titers as high as MVA. Despite the
difference in dose, there was no significant difference in the binding antibodies elicited by
the two vaccines. This confirmed that both poxvirus vaccines could induce good immune
responses and offer the prospect of dose sparing, which is highly desirable for a vaccine
that requires widespread implementation, such as HIV.
The HIV-1 envelope has a number of different conformations with the closed con-
formation (Tier 2 and 3) being the one that is mostly present on circulating viruses. The
Tier 1A conformation is regarded as an open conformation and Tier 1B as an intermediate
conformation. [67]. It is a general consensus that the induction of HIV Tier 2 NAbs for
the protection from HIV infection is desirable [8], although it is important not to discount
the contribution of non-neutralizing antibodies and cellular responses. While neutraliz-
ing monoclonal antibodies can protect from SHIV challenge [68], there are also examples
of vaccines which induce neutralizing antibodies that do not protect from challenge in
animal models [69]. Some insight into protection via NAbs has been gained from the
HVTN 703/HPTN 081 trial, in which participants received infusions of a NAb (VRC01)
at a dose of either 10 or 30 mg per kilogram [70]. While the overall trial did not prevent
HIV acquisition, the incidence of infection with VRC01-sensitive isolates was significantly
different in VRC01 recipients vs. placebo (estimated prevention efficacy, 75.4%; 95% CI,
45.5 to 88.9), indicating the protection from VRC01 sensitive viruses. This implies that
NAbs, at an appropriate titer, can protect from infection with sensitive viruses. Some
differences were observed in Tier 1A NAbs titers at various time points. The lowest Tier 1A
titers were observed in the DDLLMM group after two LSDVGC5 immunizations (DDLL).
The clearest neutralization differences could be seen in the Tier 1B NAb responses elicited.
All five rabbits in the DDLMLM group, three out of five rabbits from the DDLLMM group,
and two out of five in the DDMLML group, developed low levels of Tier 1B NAbs. In the
DDMMLL group, Tier 1B antibodies were detected after two MVAGC5 boosts, but not
after the subsequent LSDVGC5 boosts. Three out of five rabbits from the DDLLMM had
Tier 1B antibodies after the fourth poxvirus boost, but none were detected after the first two
LSDVGC5 immunizations. All five rabbits had Tier 1B antibodies in the DDLMLM group,
with two rabbits having antibodies after the first two immunizations and all five after four
poxvirus immunizations. The Tier 2 NAb responses were disappointing; however, two out
of five rabbits in the DDLMLM group developed low level autologous Tier 2 NAbs after
the fourth poxvirus boost. As mentioned earlier, additional targeted sequence changes
to improve the structure and antigenicity of the CAP256.SU Env used in this study can
increase the levels of autologous Tier 2 NAbs elicited by the different vaccination regimens.
In summary, the best antibody responses were observed in the DDLMLM group with
the alternating combination of the two different poxvirus vectors. Increasing the time
between homologous boosts might have resulted in a better response. Moreover, two
MVAGC5 immunizations (DDMM) induced Tier 1B Nabs, which were not induced by
LSDVGC5 (DDLL).
Poxviruses have been shown to differ with respect to the type of immune responses in-
duced. HIV-specific humoral and cellular immune responses were compared in macaques
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vaccinated with NYVAC (orthopoxvirus) and ALVAC (avipoxvirus). Two doses of the
poxvirus followed by two doses of the poxvirus plus gp120 protein were given to the
animals [71]. NYVAC induced higher antibody responses to HIV Env and showed a
trend towards eliciting higher cellular responses. An analysis of the transcriptome follow-
ing infection of mice with LSDV, MVA, canary poxvirus, fowlpox virus, and two novel
avipoxviruses showed that all six poxviruses induced distinct gene expression profiles.
LSDV caused the most significant response in comparison to the other poxviruses, both
in the magnitude and breadth of type 1 interferon responses and in the number of up-
regulated genes involved in antigen processing and presentation pathways. CNPV and
FWPV induced the up-regulation of the immunoglobulin gene expressing IgG3. Env IgG3
antibodies that mediated antibody-dependent cellular cytotoxicity (ADCC), or antibody-
dependent cellular phagocytosis (ADCP), correlated with a decreased risk of infection in
the RV144 trial; however, these responses decreased more than 10-fold in the first 6 months
after the vaccination [62,72]. Thus, a vaccine vector or regimen that elicits more durable
Env IgG3 antibody responses is desirable. The durability of antibody responses was not
assessed in this study; however, based on the results of Palli et al. [11], it is likely that an
MVA or LSDV boost could elicit long lasting antibody responses.
Heterologous vaccine regimens often generate better immune responses than homolo-
gous regimens [33,36,72]. However, no obvious differences were observed in the antibody
responses after two heterologous poxvirus boosts, when compared to the two homologous
boosts in this experiment. Previous work, carried out by our group in macaques, demon-
strated that the combination of MVA and LSDV generated broader, higher magnitude T cell
responses than either vector alone [28]. However, these vaccines expressed a polyprotein
of HIV-1 Gag, RT, Tat, and Nef (Grrtn) and no envelope; therefore, antibody responses to
Env were not assessed. It is likely that the vaccine regimens described in this study elicited
different cellular immune responses. Given that Gag-specific T cell responses have been
shown to correlate with viraemic control [32], comparing this response would have been
informative. Unfortunately, due to the limitation of the rabbit model, no suitable tools were
available to assess T cell responses in this experiment.
Veterinary studies have shown the T cell response to LSDV to be critical for the
protection against disease. A large proportion (approximately 50%) of vaccinated animals
do not develop antibody responses, yet they are protected against LSD [16]. The interplay
between humoral and T cell responses is not fully understood for LSDV, but both arms of
the immune response are recognized as being important [27,73,74]. A balanced CD4+ and
CD8+ T cell response specific to LSDV was elicited against a dual vaccine against LSDV
and Rift Valley fever virus [75].
Improvements were made to the HIV-1 antigens used in LSDVGC5, compared to
the LSDVgrrtn utilized in previous studies carried out by our group [28,29]. Grrtn was
replaced with a subtype C mosaic ag which forms virus-like particles and a modified
envelope gene was included. The binding and neutralizing antibody responses elicited
against HIV-1 Env by the recombinant LSDVGC5 were comparable to those induced by
MVAGC5 but did not show any significant advantages over previously used poxvirus
vectors. Targeted sequence changes to the envelope could be carried out to improve the
neutralizing antibody responses. Furthermore, more in-depth studies investigating the T
and B cell responses elicited by the LSDV-vectored HIV vaccine in non-human primates or
mice are warranted. These studies should include an assessment of both neutralizing and
non-neutralizing antibody responses.
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